Drug profile · INN
regorafenib hydrate
STIVARGA INITIAL APPROVAL
regorafenib hydrate (STIVARGA INITIAL APPROVAL) is a discoidin domain-containing receptor 2 inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — regorafenib hydrate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
regorafenib hydrate (STIVARGA INITIAL APPROVAL) is a discoidin domain-containing receptor 2 inhibitor.
Key facts
INN regorafenib hydrate
Brand STIVARGA INITIAL APPROVAL
Mechanism Discoidin domain-containing receptor 2 inhibitor
Target Discoidin domain-containing receptor 2
Mechanism of action
Discoidin domain-containing receptor 2 inhibitor
Primary target: Discoidin domain-containing receptor 2
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is regorafenib hydrate?
regorafenib hydrate (STIVARGA INITIAL APPROVAL) is a discoidin domain-containing receptor 2 inhibitor.
What is the brand name for regorafenib hydrate?
STIVARGA INITIAL APPROVAL is a marketed brand name for regorafenib hydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.